 Systemic treatment of advanced CRC has changed considerably in the last ten years with the introduction of active drugs such as oxaliplatin, irinotecan, and capecitabine. The most commonly used first line regimens are 5-Fluorouracil-Leucovorin-Oxaliplatin FOLFOX, Capecitabine-Oxaliplatin XELOX, 5-Fluorouracil-Leucovorin-Irinotecan FOLFIRI and, to a lesser extent, Capecitabine-Irinotecan XELIRI. Chemotherapy regimens are combined with different agents against therapeutic targets, three of which are effective in colon cancer: bevacizumab, which targets vascular endothelial growth factor VEGF and cetuximab or panitumumab, which target the epidermal growth factor receptor EGFR. 